QUESTION:“What was the keycatalyst for Neuron? FDA approval?”
RESPONSE
A) The chart I shared (extracted from NextInvestors) is an exact share price tracker for Neuren Pharmaceuticals, from 2021 toJanuary 2024 (not just 2021). The comments that Next have inserted, show the'catalysts' that preceded (or ‘led’) to the share price re-rates.
B) I have redone this as a table (attached) andextracted additional information from Neuren (just theannouncements). As can be seen, whenmatching events to share price re-rates, the Top 3 SP catalysts were:
1) Trial results (Retts) - (Announced 6th of Dec 2021). This caused the biggestjump to date!
2) FDA approval - (Announced 14th of March 2023). This caused the nextbiggest jump to date.
3) Trial results (Phelan-McDermid) - (Announced 18 Dec 2023). This is not markedon the Next Investors chart - they limited their comments (on the chart) to Rett Syndrome!
| DATE | EVENT (CATALYST) | SHARE PRICE MOVES (5 days) |
|---|
| 1 | 07 Dec 2021 | ANN: Positive topline results from Phase 3 trial in Rett syndrome | $1.70 to $4.00 (135%) |
|---|
| 2 | 14 Mar 2023 | ANN: FDA approves Daybue - the first treatment for Rett syndrome | $7.60 to $12.80 (68%) |
|---|
| 3 | 18 Dec 2023 | ANN: P2 trial shows significant improvements in Phelan-McDermid | $16.00 to $24.00 (50%) |
|---|
The share price movements within those 2 to 5days post results were much higher than what happened in the interveningperiods: 6% per month rise from Rett P3 results to FDA announcement, and 2.7%per month rice post the FDA announcement up to the P2 Phelan-McDermid trialresults readout.
Indeed, NT1 is still behind. This is shownclearly on the Next Investors chart.
